Kazia swipes an ex-Sanofi mol­e­cule for £1M up­front as they look to repli­cate their Genen­tech snag

Kazia has spent most of its young life try­ing to de­vel­op a sin­gle Genen­tech castoff it swiped for $5 mil­lion in­to a brain can­cer drug. Now, with that mol­e­cule in a piv­otal tri­al, the Aussie biotech is adding an­oth­er old Big Phar­ma as­set to its re­serves.

Kazia an­nounced Mon­day they in-li­censed a small mol­e­cule called EVT801 from Evotec for a nom­i­nal up­front fee – $1.4 mil­lion — and $428 mil­lion in po­ten­tial mile­stones. The com­pa­ny said they plan to launch a Phase I tri­al for the drug, a new VEG­FR in­hibitor, lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER